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ABSTRACT  
 
 Tau is an intrinsically disordered microtubule-associated protein that is implicated in several 
neurodegenerative disorders called Tauopathies. In these diseases, Tau is found in the form of 
intracellular inclusions that consist of aggregated paired helical filaments (PHFs) in neurons. 
Given the importance of this irreversible PHF formation in neurodegenerative disease, Tau 
aggregation has been extensively studied. Several different factors, such as mutations or post 
translational modifications, have been shown to influence the formation of late-stage non-
reversible Tau aggregates. It was recently shown that zinc ions accelerated heparin-induced 
oligomerization of Tau constructs. Indeed, in vitro studies of PHFs have usually been performed 
in the presence of additional co-factors, such as heparin, in order to accelerate their formation. 
Using turbidimetry, we investigated the impact of zinc ions on Tau in the absence of heparin and 
found that zinc is able to induce a temperature-dependent reversible oligomerization of Tau. The 
obtained oligomers were not amyloid-like, and dissociated instantly following zinc chelation or a 
temperature decrease. Finally, a combination of isothermal titration calorimetry and dynamic 
light scattering experiments showed zinc binding to a high affinity binding site and three low 
affinity sites on Tau, accompanied by a change in Tau folding. Altogether, our findings stress the 
importance of zinc in Tau oligomerization. This newly identified Zn-induced oligomerization 
mechanism may be a part of a pathway different of and concurrent to Tau aggregation cascade 
leading to PHF formation.  
 
 
Keywords: Tau, zinc, aggregation self-assembly 
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INTRODUCTION 
Microtubule associated protein Tau is known to play a vital role in cytoskeleton regulation by 
binding tubulin and thus controlling essential microtubule (MT) functions, from the necessary 
dynamic instability in dividing cells to axonal stability in neurons [1, 2]. Tau is also associated 
with a number of neurodegenerative diseases (ND) including Alzheimer’s disease (AD), 
Parkinson's disease (PD), Pick’s disease, Frontotemporal lobar degeneration (FLTD), 
Corticobasal degeneration and Progressive supranuclear palsy where it forms intracellular 
aggregates [3-6]. These aggregates would spread in the brain through prion-like propagation [3, 
7]. In the case of AD, Tau is believed to be the main factor underlying the development and 
progression of the pathology [8]. Different types of inclusions made of abnormal forms of Tau 
are found in different areas of the nervous system mostly in neuronal cells and, in some cases, in 
glial cells. The most common form of inclusions is called neurofibrillary tangles (NFTs). They 
are found in Alzheimer’s disease, Parkinson's disease as well in other Tauopathies and consist of 
stacked paired helical filaments (PHFs) of hyper-phosphorylated Tau molecules [9]. In some 
diseases, Tau-mediated neuronal death can occur even in the absence of tangle formation [10] 
and it often aggregates with other teammates such as amyloid-β or α-Synuclein [11, 12]. Despite 
the extensive study of Tau aggregation over the last two decades, the exact causes of this process 
as well as its molecular mechanism are still not completely elucidated. PHF remains the most 
studied form of Tau aggregates. Among the endogenous factors that have been shown or 
suggested to favor Tau aggregation are post-transitional modifications (in particularly hyper-
phosphorylation), mutations and the presence of zinc ions [13-16]. Interestingly, zinc ions were 
found to play a critical role in the development of several different neurodegenerative diseases 
including AD and PD. Zinc can bind not only to a number of prone-to-aggregate proteins 
implicated in neurodegeneration (such as amyloid-β [17], FUS/TLS [18], α-Synuclein [19], 
TDP-43 [20, 21] etc.) and favor their aggregation, but also induce aggregation of stable proteins 
[22].  
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The potential impact of zinc ions on Tau aggregation/oligomerization was first discovered in 
2009 [23]. It was shown that low micromolar concentrations of zinc are able to accelerate the 
fibrillization of the 244-372 aa fragment of human Tau40 (hTau40), which consists of the four 
MTBR binding repeats R1, R2, R3 and R4 [23]. Similar results have been recently obtained on 
this same fragment lacking R3 repeat [24]. Nevertheless, both studies were carried out in the 
presence of heparin, which induces Tau fibrillization into ThT-positive paired helical filaments 
(PHFs). Recently, it was demonstrated that zinc not only accelerates aggregation of a 
pathological mutant ΔK280 of hTau40 induced by Congo red in vitro, but also significantly 
increases its toxicity in neuronal cells [25]. This study also demonstrated the importance of Cys-
291 and Cys-322 residues both for zinc binding and Tau aggregation [23, 25]. While using non-
physiological specific inductors of Tau aggregation such as heparin or Congo red is the most 
common way to induce PHFs structure and test inhibitors, it might not be the most pertinent 
model to study PHF formation itself, especially in the early stages where the process has already 
been hypothesized to be reversible  [26]. Also, it should be noted that in these studies the 
pathological aggregation in the presence of zinc were demonstrated for Tau mutants and 
fragments that could have higher propensity to aggregate in comparison with wild type human 
full-length Tau (hTau40).  
Here, we have investigated aggregation of full-length human hTau40 isoform in the absence of 
heparin but in the presence of zinc ions under a wide range of temperature conditions using 
turbidimetry, isothermal titration calorimetry, dynamic light scattering and transmission electron 
microscopy. We found that, contrary to its aggregation in the presence of heparin or with other 
inducers such as arachidonic acid or congo red [25, 27, 28], self-assembly of Tau is a reversible 
process that depends on temperature and is induced by zinc ions. Moreover, our findings point to 
an important role of low affinity auxiliary zinc-binding sites in this process. 
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RESULTS 
Zinc ions induce Tau oligomerization.  
Turbidimetry was used to monitor the impact of zinc on Tau self-assembly in the absence 
of heparin at different temperatures. The absorbance (ΔA 350 nm) of 30 µM Tau samples at 
different ZnCl2 concentrations (from 0 to 240 µM) in 50 mM Tris buffer, 1 mM TCEP at pH 7.5 
was measured over a wide range of temperatures from 15 to 95°C (Fig.1A). In the absence of 
zinc ions as well as in the presence of low ZnCl2 concentrations (15 µM) Tau protein did not 
demonstrate any propensity to aggregate. Increasing zinc concentration, starting from a Zn/Tau 
molar ratio of 1, led to a pronounced rise in the turbidity upon sample heating, which could 
indicate the formation of large oligomers of Tau. We found that Tau protein started to form 
oligomers at lower temperatures when higher zinc concentrations were used. Indeed, a 2-fold-
excess zinc induced Tau assembly at near physiological temperatures while in the presence of an 
8-fold zinc-excess, Tau was already partially assembled at 15°C. In parallel, to investigate the 
reversibility of this observed assembly, Tau sample was heated to 37°C and cooled down to 
13°C in the presence of 4-fold zinc excess (120 µM of ZnCl2). Each time, absorbance increased 
upon heating and dropped after cooling demonstrating near 100% reversibility of the 
oligomerization (Fig.1B). 
Thermodynamics of Tau-zinc interaction. 
To verify if Tau oligomerization is directly linked to zinc binding, we investigated Tau-
zinc interaction using isothermal titration calorimetry (ITC) at different temperatures. In the 
turbidimetry experiments, at low temperatures we observed Tau aggregation only at high zinc 
concentrations (above 120 µM), but at high temperatures Tau aggregation started at an equimolar 
zinc concentration. ITC titration of 30 µM Tau solution by zinc at 10 and 45°C did not reveal 
significant differences in thermodynamic parameters of Tau-zinc interaction (Fig.2) indicating 
that zinc binds to tau just as well at 10°C than at 45°C. In both cases, fitting the binding 
isotherms using a two-sets-of-sites model revealed the existence of one high affinity site for zinc 
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(N=1.0±0.1; Ka=2.0±0.5×106 M-1) and three low affinity sites (N=3.2±0.3; Ka=5.9±1.7×104 M-1). 
The high affinity site was enthalpy driven but entropy unfavorable (∆H = -12.1±0.2 kcal M-1; ∆S 
= -13.8 cal M-1 K-1) probably due to partial folding of initially unstructured Tau molecule. 
Meanwhile, the three low affinity sites were both enthalpy and entropy favorable (∆H = -1.8±0.3 
kcal M-1; ∆S = 15.4 cal M-1 K-1) pointing to the burying of hydrophobic surfaces upon 
interactions during Tau aggregation. 
Characterization of Tau oligomers. 
To characterize the oligomers of Tau that form in the presence of zinc ions we used 
dynamic light scattering (DLS), transmission electron microscopy (TEM) and Thioflavin-T 
assay. DLS analysis of 30 µM Tau solution showed that, in the absence of zinc, at 10°C, Tau is 
mostly represented in solution as a species with a median hydrodynamic diameter of 9.6 ±1.4 nm 
by mass (Dv50, Table 1). Given that Tau is an intrinsically disordered protein, this size would 
correspond to the unfolded monomer [29]. Heating up to 40°C did not reveal significant 
conformational changes of the monomeric state of Tau (Table 1), in agreement with our 
turbidimetry data. 
To investigate the impact of zinc ions on the oligomeric state of Tau, 30 µM of Tau was 
titrated with up to a 4-fold molar excess of zinc at 40°C and analyzed by DLS (Fig. 3A-C). 
Within this range of zinc concentration, the main Tau species represented by mass had diameters 
ranging between from 10 to 12 nm. Furthermore, below the molar ratio Zn/Tau of 2.3 the 
polydispersity index remained low while Z-average (mean particle size) gradually increased 
(Fig. 3C; Table 1). Above this Zn/Tau ratio, Z-average started to increase together with the 
polydispersity indicating protein aggregation (Fig. 3C). Further increases in zinc concentration, 
up to excess of 4, led to a complete disappearance of low size species (Fig. 3A, B) and the 
formation of oligomers too large to be properly monitored by DLS. Further investigation of 
formed structures by electron microscopy revealed the existence of large (>10 µm) aggregates 
(Fig. 3E), which are in a good agreement with our DLS experiment. Indeed, as shown in the 
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correlograms (Fig. 3D), as the concentration of zinc increases, the decay time increases, which 
indicates an increase in Tau size. Characterization of Tau oligomerization using Th-T assay (Fig. 
3G) did not reveal the presence of amyloid-like structures. 
When the temperature was then decreased from 40°C to 10°C, we observed the 
reappearance of low size species with a Dv50 of 11.3±2.5 nm in the presence of 120 µM zinc 
(Table 1) which indicates that the oligomerization induced by zinc at 40°C is reversible. 
Moreover, chelation of zinc ions with high excess of EDTA (2 mM) at 40°C also led to complete 
dissociation of aggregates, which returned to the same size distribution as it was before addition 
of zinc ions (Table 1). We have thus shown that reducing temperature can reverse the effect of 
zinc oligomerization of Tau and that removal of zinc at high temperatures can also reverse the 
oligomerization of Tau.  
 
DISCUSSION 
Zinc, which plays an important role in many physiological processes, has been implicated 
in the molecular mechanisms of many neurodegenerative diseases by favoring aggregation of 
proteins such as amyloid beta, FUS, TDP-43 [21, 30]. Recent in vitro studies showed that zinc 
could also impact Tau aggregation into PHF, a hallmark of several Tauopathies. Nevertheless, 
the conclusions from these studies were limited by the fact that the oligomerization of Tau into 
PHFs was induced by heparin.  
Here, for the first time, we demonstrated that the presence of the zinc ions combined with 
increased temperature is sufficient to induce a fast oligomerization of Tau, and that it is 
reversible. Indeed, we have found that in the presence of equimolar zinc concentration, Tau 
oligomerizes at 50°C, while the increase of molar ratio of Zn/Tau to 2 decreases the temperature 
of oligomerization to 32°C (Fig. 1), thus potentially impacting physiological function of Tau. 
Similar interplay between ions and temperature of polymerization has already been observed in 
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other important physiological systems such as Mg2+/tubulin wherein tubulin polymerization 
depends both on temperature and Mg2+ concentration [31]. 
Characterization of Zn/Tau binding by ITC at different temperatures allowed us to 
demonstrate that the thermodynamics of the interaction is the same whether Tau oligomerizes or 
not. Indeed, the binding isotherms registered at 10°C (where oligomerization is only triggered by 
high zinc concentrations) and 45°C (where oligomerization starts at the beginning of titration) 
are almost identical. At both temperatures, ITC demonstrates the existence of 2 types of sites, 
one site with a high affinity (Ka=2.0±0.5×106 M-1) and three sites with a low affinity 
(Ka=5.9±1.7×104 M-1), which could have different functions. DLS showed that upon saturation 
of the high affinity site, the hydrodynamic diameter of Tau species dropped from 12.2 to 10.8 
nm and remained stable at 10.5 ± 0.22 nm until a molar ratio Zn/Tau of 2.3 (Fig.3B). This 
suggests a partial folding of Tau with an increase in homogeneity as shown by the polydispersity 
index (Pdi). This is also in agreement with the unfavourable entropy of zinc binding found by 
ITC for this site. This first high affinity site likely corresponds to the one localized in the R2-R3 
Tau region in which zinc is chelated by two Cys and two His amino acids, as previously 
proposed [23, 25]. Such binding would be accompanied by the folding of Tau in R2-R3 as a 
hairpin, which is in good agreement with our DLS data that showed a compaction of the 
molecule. The three low affinity sites may be responsible for the oligomerization process. 
Indeed, at 40°C we start to detect oligomerization by DLS at Zn/Tau around 2, when zinc starts 
to bind to these low affinity sites, as it can be seen from ITC titration curve (Fig 2). Interestingly, 
the hydrodynamic size of Tau monomer species continues to decrease (down to 8.9±1.2 nm) as 
zinc binds to auxiliary sites, pointing to a further Tau folding (Fig. 3C). This leads us to propose 
that zinc binding to both types of sites induces a structural change that may have a consequence 
on Tau physiological functions.  
It should be stressed that, contrary to heparin-induced fibrillization of Tau in most PHF 
models, zinc-induced oligomerization of Tau is a reversible process with fast kinetics. Indeed, 
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chelation of zinc ions using EDTA, or a decrease of temperature instantly led to dissociation of 
oligomers. Contrary to ThT-positive irreversible aggregates formed in the presence of heparin, 
oligomers induced by zinc ions were not only reversible but also ThT-negative which indicates 
that the oligomers in the absence of heparin formed are not amyloid like. Most of the previous 
studies of Tau self-association in vitro were carried out in the presence of agents such as heparin 
or arachidonic acid [27, 28] and led to generation of irreversible structures. It has been 
hypothesized, and widely accepted, that irreversible Tau aggregation leading to PHFs found in 
neurons of patients affected with neurodegenerative disease would be preceded by a stage of 
reversible Tau multimers formation [26]. In our study, for the first time, we were able to 
reproduce a reversible oligomerization of Tau proteins in the presence of Zn without any 
additional non-physiological additives. Thus, our experimental conditions could constitute a 
useful model to study Tau multimerization in vitro. 
The reversibility of Tau structures observed in our experiments also allows us to 
hypothesize that oligomers could be induced in cells by zinc signals under physiological 
conditions and play a role in Tau regulation, modulating its numerous functions [1]. For 
example, zinc was found to be involved in regulation of Tau interaction with DNA [32]. More 
generally, zinc is abundantly present in the brain where it plays an important role in axonal and 
synaptic transmission [33, 34]. It is highly concentrated in the synaptic vesicles of several types 
of neurons [35]. The majority of zinc ions in cell are bound to metalloproteins, which have metal 
binding affinities in the nM and even in pM range. The physiological concentration of free Zn2+ 
in cells is considered to be between around 1-10 nM [36, 37] which locally would be sufficient to 
bind to Tau and modulate its activity. Thus, the observed binding constants that we determined 
are consistent with the possible physiological role of Zn in Tau regulation.  
 
 
CONCLUSION  
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In conclusion, we demonstrated for the first time that zinc can induce a reversible 
polymerization of Tau. This process could have a significant function in the brain and nervous 
system where zinc is known to be abundant. Our data, which demonstrate that zinc favors Tau 
self-assembly at near physiological temperatures, supports the idea that zinc could be implicated 
both in the pathological aggregation of Tau as well as in tau regulation.  As summarized in figure 
4, while the right part depicts the irreversible cascade leading to the formation of neurofibrillary 
tangles, the left part depicts a pathway which would ultimately lead to the formation reversible 
granular aggregates of Tau which could have a sequestration purpose. Since tau phosphorylation 
is known to have physiological and pathological consequences [38], impact of tau 
phosphorylation on this pathway will need to be addressed. We have also shown the existence of 
two types of sites (one main and three auxiliary ones) that gradually modulate Tau structure 
enabling zinc to be a subtle modulator of Tau activity. In order to understand how zinc ions can 
impact physiological Tau oligomerization, it will be important to identify the specific amino 
acids responsible for binding of those auxiliary zinc ions and the structure of such oligomers. 
Likewise, confirming that this reversible oligomerization of Tau is part of a concurrent pathway 
will have important consequences in neurodegenerative disease research. 
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MATERIALS AND METHODS 
Protein purification 
Human Tau (hTau40) was expressed in E. coli and purified as described previously [39]. Tau 
could thus be directly resuspended before use in the appropriate buffer. Protein was passed 
through the Zeba Spin Desalting Columns (Thermo Scientific) to equilibration in Tris 50 mM, 
TCEP 1mM, pH 7.5 buffer before being used for experiments. TCEP was used to maintain Tau 
in a reduced state. Its concentration was measured at 280 nm using extinction a coefficient of 
7700 M-1 cm-1 [31]. 
Isothermal Titration Calorimetry (ITC) 
Binding of zinc to Tau was analyzed by ITC using MicroCal iTC200 as described previously 
[40, 41]. Experiments were performed at 10 and 45°C and in 50 mM Tris buffer in the presence 
of 1 mM TCEP, pH 7.5. Tau concentration in the calorimetric cell was 30 μM, whereas the 
ZnCl2 concentration in the syringe was 600 μM. Tau was titrated by repeated injections of 2 μL 
aliquots of zinc solution. At the end of titration, the cell contained the mixture of zinc and Tau 
with the molar ratio equal to 4:1.  The syringe was refilled with the same zinc solution without 
cell refilling and the titration was continued until the final ratio of 8:1. Each resulting titration 
peak was integrated and plotted as a function of the Tau/tubulin molar ratio. The baseline was 
measured by injecting ZnCl2 into the protein-free buffer solution. Data were analyzed using 
Origin software and were fitted with a “two set of sites” model via a non-linear least squares 
minimization method and led to the determination of affinity constants (Ka) and enthalpy 
changes (ΔH). Thermodynamic values are an average of at least three different experiments. 
Turbidimetry 
Tau polymerization was monitored by turbidimetry (A 350 nm) using a Perkin-Elmer 
spectrophotometer Lambda 800 (Perkin-Elmer) and a Prometheus NT.Plex (Nanotemper) 
instrument equipped with absorbance module with a heating rate of 1 K/min. Purified Tau (30 
μM) was equilibrated in 50 mM Tris, 1 mM TCEP, pH 7.5 buffer in the absence or in the 
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presence of zinc and incubated at 5°C. Polymerization was initiated by temperature increase to 
40°C and reversed by cooling sample to 13°C. 
Dynamic Light Scattering (DLS) 
Dynamic light scattering (DLS) experiments were carried out to determine the hydrodynamic 
diameter of Tau in the presence and absence of zinc using a Zetasizer Nano ZS (Malvern 
Instruments) with a scattering angle of 173°.  Particles in solution are in constant random motion 
and the intensity of their scattered light fluctuates with time. To determine the hydrodynamic 
diameter (Dh), the provided software uses the Stokes-Einstein relation to obtain the intensity 
averaged size distribution from the raw correlation data. The correlogram displays much 
information about the sample. The time at which the correlation starts to decay is an indication 
of the mean size of the sample. Smaller samples fluctuate quicker than larger samples in 
solution. The steeper the exponential decay, the more monodisperse (single population) the 
sample, and the more the decay is extended the greater the sample polydispersity (several 
populations) which is indicated by the polydispersity index (PDI). To analyze Tau, DLS was 
performed at temperatures ranging from 10 to 40°C. For each assay three measurements were 
performed; each one consisting in 10-15 runs of 10 seconds. Tau was analyzed at 30 µM in 50 
mM Tris, 1 mM TCEP, pH 7.5 following centrifugation for 15 minutes at 14000 rpm at 6°C.  
The overall thermostability and aggregation of Tau was tested in the absence and presence of 10-
120 µM of ZnCl2. To determine the hydrodynamic diameter (Dh), the viscosity and refractive 
index values of the dispersion medium was used in the stokes-Einstein equation. In our case, we 
used a viscosity of 1.3198 cP and a refractive index of 1.331 (at 10°C). Results were displayed as 
volume and intensity size distributions including the overall mean size (Z-average) using the 
Zetasizer software 7.12 with a detailed high-resolution spectrum of 300 classes. All experiments 
were performed at least in triplicates. 
Fluorescence Thioflavin T (ThT) assay 
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ThT assay, which is a common marker of amyloid fibrils was performed as described before [42] 
with some modifications. Briefly, samples of 30 µM Tau alone or Tau with 8-fold excess of 
ZnCl2, were mixed with ThT. Fluorescence spectra were acquired in 0.2 (excitation direction) x 
1 cm (emission) cells (Hellma) thermostated at 37°C ± 0.5°C without pre-incubation. Excitation 
was at 440 nm and emission spectra were recorded from 460 to 520 nm with slit widths of 15/15 
nm using a Perkin-Elmer LS 55 fluorescence spectrometer operating at a PM of 800 V. 
Transmission electron microscopy (TEM) 
Four microliters of incubated Tau samples (30 µM) were placed on carbon-coated copper grids 
(300 mesh) during 1 min. After blotting, grids were washed with distilled water, and blotted 
again, negatively stained for 30 seconds with 2% (wt/vol) uranyl acetate as previously described 
[21]. The grids were then dried and observed with a JEOL 2200FS transmission electron 
microscope (Tokyo, Japan) operating at 200 kV. Images were recorded using a 4k × 4k slow-
scan CCD camera (Gatan, Inc. Pleasanton, USA).  
 
 
 
Table 1. Characteristics of Tau polymers in presence of different zinc concentrations by 
DLS.  
 
T, °C [ZnCl2], µM Z-average, nm Pdi Dv50, nm Di50, nm 
10 0 14.3±0.7 0.31±0.02 9.6±1.4 13.7±1.1 
40 0 20.0±2.1 0.50±0.07 12.2±0.6 13,0±0.5 
40 30 55.1±63.7 0.30±0.13 10.5±0.4 12.2±0.2 
40 60 193.3±46.1 0.21±0.02 11.4±0.2 11.4±0.2 
40 90 3158.0±1462.0 0.99±0.02 8.8±1.1 8.9±1.2 
40 120 99000.0±20000.0 OOR OOR OOR 
10* 120 26.0±9.6 0.27±0.08 11.3±2.5 13.2±0.3 
40 90** 55.2±30.2 0.41±0.05 11.3±0.3 12.2±0.4 
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Z-average - mean intensity size (diameter) of sample; Pdi - polydispersity index; Dv50 - Volume 
based diameter median; Di50 - Intensity based diameter median in nm; * - sample cooled from 
40 to 10°C; ** - 2 mM EDTA added; OOR – out of range 
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Abbreviations: MT: microtubule; ND: neurodegenerative diseases; AD: Alzheimer’s disease; 
PD: Parkinson's disease; FLTD: Frontotemporal lobar degeneration; NFT: neurofibrillary 
tangles; PHF: paired helical filaments; ThT: Thioflavin; ITC: Isothermal Titration Calorimetry; 
DLS: Dynamic Light Scattering; TEM: Transmission electron microscopy. 
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Figures 
 
Fig.1. (A) Temperature dependence of 30 µM tau samples turbidity in the absence of ZnCl2 
(black curve) and in the presence of 0.5, 1, 2, 3, 4 and 8-fold molar excess of ZnCl2 (see color 
legend on the right) in 50 mM Tris buffer, 1 mM TCEP, at pH 7.5 obtained using Prometheus 
NT.Plex instrument. (B) Reversible aggregation of tau (30 µM) followed by turbidimetry in the 
presence of 4-fold molar excess of ZnCl2 (yellow curve); control tau sample in the absence of 
zinc (black curve); variation of temperature during experiment (black dotted line). Measurements 
were carried out using Perkin-Elmer spectrophotometer Lambda 800. 
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Fig.2. Typical ITC titration curves (top panel) and binding isotherms (bottom panel) for zinc at 
10°C (black) and at 45°C (red) interactions with 30 µM of tau in 50 mM Tris, 1 mM TCEP, pH 
7.5.  
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Fig 3. Size distribution by volume (A) and by intensity (B) of 30 µM tau in the absence of zinc 
(orange curve) and in the presence of 30 and 60 µM zinc (in red and burgundy respectively) at 
40°C. (C) Correlation coefficient versus time in µs for Tau 30 µM in the presence of 0, 10, 60 
and 100 µM ZnCl2 (shown in colors orange, red, burgundy and black respectively). (D) Median 
volume based diameter (DV50) in nm (blue), polydispersity index (Pdi) (orange) and Z-average - 
mean intensity size in (black) for different zinc/Tau molar ratio, with Tau 30 µM. (E) and (F) 
Representative electron micrographs of negatively stained Tau aggregates at 37°C in the 
presence and in the absence of zinc ions respectively. (G) Representative electron micrographs 
of negatively stained sample of Tau in the presence cooled down from 37°C to 10°C. (H) 
Fluorescence spectra of ThT at 60 µM in buffer (dotted curve), in the presence of zinc-induced 
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Tau aggregates (black curve) and in the presence of heparin-induced Tau aggregates (blue line) 
used as positive control. 
 
 
 
 
Fig 4 Model. The right part of the scheme corresponds to the pathway leading to PHFs and NFT 
formation. This pathway is globally irreversible and favored by post translational modifications 
sur as (hyper) phosphorylation of Tau, and Zn2+.  The left part of the scheme summarizes our 
findings: in the presence of low Zn2+ concentrations, Tau undergoes compaction; in the presence 
of high Zn2+ concentrations it leads to the formation of granular Tau oligomers. This pathway is 
fully reversible.  
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Highlights 
 
x Tau aggregation mechanism is still poorly understood 
x Zinc ions induce fast and reversible oligomerization of Tau without heparin 
x Tau has 2 types of Zinc binding sites  
x Zinc ions binding to tau induces structural changes of tau 
x New oligomerization mechanism might be concurrent to PHF formation.  
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